Actively Recruiting
Study of VVD-133214 Combined With Pembrolizumab Versus Pembrolizumab Alone in Advanced Colorectal Cancer With MSI or dMMR
Led by Vividion Therapeutics, Inc. · Updated on 2026-10-21
140
Participants Needed
122
Research Sites
130 weeks
Total Duration
AI-Summary
What This Trial Is About
Researchers are exploring new treatment options for people with advanced colorectal cancer that has spread or cannot be removed by surgery. This cancer type, affecting the colon or rectum, sometimes involves problems with the bodys DNA repair system called dMMR or a condition called MSI. These issues can cause cancer cells to rely on a protein called Werner helicase to survive. Blocking this protein might help stop cancer growth with less harm to healthy cells. This Phase 2 study evaluates a drug named VVD-133214 that blocks Werner helicase, combined with pembrolizumab, an immunotherapy drug approved to help the immune system attack cancer cells. Participants in this trial will receive oral VVD-133214 along with pembrolizumab given by intravenous infusion every three weeks. The study compares this combination to pembrolizumab alone to find the best dose of VVD-133214 and to assess whether the combination works better. Participants will receive VVD-133214 as long as it remains helpful without causing serious side effects, while pembrolizumab treatment will continue for up to two years. Participants may stop treatment at any time. During the trial, participants will have regular visits for tests, scans, and health check-ups to monitor how their cancer responds and to track any new or worsening medical problems. After stopping treatment, follow-up visits will occur 30 days after the last VVD-133214 dose and 100 days after the last pembrolizumab dose. Long-term follow-up visits will continue every 90 days as long as participants agree to remain in the study. The main outcome measured is the progression-free survival rate at six months, with safety and other response measures also monitored throughout up to about 36 months.
CONDITIONS
Brief Title
A Study to Evaluate the Efficacy of VVD-133214 in Combination With Pembrolizumab Compared With Pembrolizumab Alone in Participants With Advanced Cancer of the Colon or Rectum
Research Team
B
Bayer Clinical Trials Contact
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here